Table 1.
Treatment | Dose formulation | Initial dose | Most common AEs |
---|---|---|---|
Phosphate binders | |||
Calcium-containing | |||
Calcium acetate (prescription for ESRD) | 667 mg capsules | 667–1,334 mg | Nausea, vomiting, hypercalcemia |
Calcium carbonate (OTC) | 250 to 1,000 mg tablets | 500–1,000 mg | Nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence, constipation |
Non-calcium-containing | |||
Sevelamer hydrochloride/carbonate | 800 mg tablets, 2.4 g packets powder for oral suspension | 800–1,600 mg TID with meals | Headache, diarrhea, stomach upset |
Lanthanum carbonate (for ESRD) | 250, 500, 750, and 1,000 mg chewable tablets | 1,500 mg daily | Diarrhea, nausea, abdominal pain, vomiting |
Vitamin D analogs | |||
Calcitriol | Oral (0.25 µg capsules) | 0.25 µg daily | Hypercalcemia, headache, abdominal pain, nausea, rash, urinary tract infection |
Injectable (1 µg/mL) | 1–2 µg three times weekly or every other day | Weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain, metallic taste, anorexia, abdominal pain, epigastric discomfort | |
Doxercalciferol | Oral (0.5, 1.0, and 2.5 µg capsules) | 1 µg daily (predialysis) 10 µg three times weekly at dialysis |
Edema, headache, malaise, dyspepsia, nausea, vomiting, dizziness, dyspnea (similar for both dosing forms) |
Injectable 4 µg/2 mL | 4 µg three times weekly at the end of dialysis or every other day | ||
Paricalcitol | Oral (1, 2, and 4 µg capsules), injectable | 1–2 µg daily (PTH ≤500 pg/mL) or 2–4 µg every other day (PTH >500 pg/mL) | Diarrhea, hypertension, dizziness, vomiting |
Calcimimetic | |||
Cinacalcet | 30, 60, and 90 mg tablets | 30 mg once daily | Nausea, vomiting, diarrhea |
Notes: Calcium carbonate, Medline Plus Drug Information, Available from: www.nlm.nih.gov/medlineplus/druginfo/meds/a601032.html. Data from the following references.16,57–63
Abbreviations: AE, adverse event; ESRD, end-stage renal disease; OTC, over the counter; PTH, parathyroid hormone; TID, three times per day.